gefitinib has been researched along with tae226 in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (tae226) | Trials (tae226) | Recent Studies (post-2010) (tae226) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 65 | 0 | 49 |
| Protein | Taxonomy | gefitinib (IC50) | tae226 (IC50) |
|---|---|---|---|
| Chain A, FOCAL ADHESION KINASE 1 | Gallus gallus (chicken) | 0.0062 | |
| Chain A, FOCAL ADHESION KINASE 1 | Gallus gallus (chicken) | 0.0062 | |
| Chain A, FOCAL ADHESION KINASE 1 | Gallus gallus (chicken) | 0.0062 | |
| Chain A, FOCAL ADHESION KINASE 1 | Gallus gallus (chicken) | 0.0062 | |
| Aurora kinase A | Homo sapiens (human) | 0.004 | |
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | 0.86 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.55 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.71 | |
| Insulin receptor | Homo sapiens (human) | 0.036 | |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | 0.1205 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 2.6 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.75 | |
| Focal adhesion kinase 1 | Homo sapiens (human) | 0.3135 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0275 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Asano, H; Hatakeyama, S; Jida, M; Kawahara, E; Kiura, K; Kubo, T; Miyoshi, S; Naomoto, Y; Otani, H; Sakaguchi, M; Soh, J; Takaoka, M; Toyooka, S; Tsukuda, K; Ueno, T; Yamamoto, H | 1 |
2 other study(ies) available for gefitinib and tae226
| Article | Year |
|---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Protein-Tyrosine Kinases; Gefitinib; Humans; Lung Neoplasms; Mice; Morpholines; Mutation; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2015 |